COSCIENS Biopharma Inc.
CSCI.TO
TSX
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 6.91% | 19.08% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 6.91% | 19.08% | |||
| Cost of Revenue | -5.36% | 23.35% | |||
| Gross Profit | 30.21% | 11.74% | |||
| SG&A Expenses | -43.83% | 14.14% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -36.98% | 16.49% | |||
| Operating Income | 69.43% | -14.64% | |||
| Income Before Tax | 91.58% | -19.46% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 91.62% | -20.01% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 592.76% | -20.01% | |||
| EBIT | 69.43% | -14.64% | |||
| EBITDA | 91.28% | -148.33% | |||
| EPS Basic | 599.35% | -19.80% | |||
| Normalized Basic EPS | 91.47% | -37.37% | |||
| EPS Diluted | 599.10% | -19.80% | |||
| Normalized Diluted EPS | 91.47% | -37.37% | |||
| Average Basic Shares Outstanding | -1.32% | 0.18% | |||
| Average Diluted Shares Outstanding | -1.32% | 0.18% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||